OBIO Orchestra BioMed Holdings Inc
Price (delayed)
$4.23
Market cap
$160.8M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.61
Enterprise value
$137.03M
Highlights
Orchestra BioMed Holdings's debt has plunged by 84% YoY but it has increased by 27% from the previous quarter
The equity has contracted by 42% YoY but it has grown by 4.7% from the previous quarter
OBIO's net income is down by 25% YoY and by 3.8% QoQ
Orchestra BioMed Holdings's quick ratio has decreased by 19% YoY and by 8% QoQ
Key stats
What are the main financial stats of OBIO
Market
Valuations
Earnings
Shares outstanding
38.01M
Market cap
$160.8M
Enterprise value
$137.03M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.46
Price to sales (P/S)
60.12
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
51.77
Revenue
$2.65M
Gross profit
$2.45M
Operating income
-$60.11M
Net income
-$57.69M
EBIT
-$54.95M
EBITDA
-$53.99M
Free cash flow
-$48.17M
Per share
Balance sheet
Liquidity
EPS
-$1.61
EPS diluted
-$1.61
Free cash flow per share
-$1.28
Book value per share
$1.22
Revenue per share
$0.07
TBVPS
$2
Total assets
$75.32M
Total liabilities
$29.1M
Debt
$1.84M
Equity
$46.22M
Working capital
$52.34M
Debt to equity
0.04
Current ratio
4.23
Quick ratio
4.13
Net debt/EBITDA
0.44
Margins
Efficiency
Dividend
EBITDA margin
-2,039.5%
Gross margin
92.7%
Net margin
-2,179.3%
Operating margin
-2,270.7%
Return on assets
-70.9%
Return on equity
-107%
Return on invested capital
-124.5%
Return on capital employed
-93%
Return on sales
-2,075.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
OBIO stock price
How has the Orchestra BioMed Holdings stock price performed over time
Intraday
3.42%
1 week
-9.81%
1 month
-22.95%
1 year
-34.82%
YTD
5.75%
QTD
5.75%
Financial performance
How have Orchestra BioMed Holdings's revenue and profit performed over time
Revenue
$2.65M
Gross profit
$2.45M
Operating income
-$60.11M
Net income
-$57.69M
Gross margin
92.7%
Net margin
-2,179.3%
Orchestra BioMed Holdings's net margin has plunged by 70% YoY but it has increased by 18% from the previous quarter
OBIO's operating margin has shrunk by 67% YoY but it is up by 19% QoQ
The company's gross profit rose by 28% QoQ but it fell by 28% YoY
Orchestra BioMed Holdings's revenue has increased by 27% QoQ but it has decreased by 26% YoY
Growth
What is Orchestra BioMed Holdings's growth rate over time
Valuation
What is Orchestra BioMed Holdings stock price valuation
P/E
N/A
P/B
3.46
P/S
60.12
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
51.77
Orchestra BioMed Holdings's EPS has decreased by 2.5% YoY
The equity has contracted by 42% YoY but it has grown by 4.7% from the previous quarter
The price to book (P/B) is 26% lower than the last 4 quarters average of 4.7
OBIO's price to sales (P/S) is 41% less than its last 4 quarters average of 102.1
Orchestra BioMed Holdings's revenue has increased by 27% QoQ but it has decreased by 26% YoY
Efficiency
How efficient is Orchestra BioMed Holdings business performance
Orchestra BioMed Holdings's return on invested capital has shrunk by 156% YoY and by 35% QoQ
OBIO's ROE has dropped by 87% year-on-year and by 20% since the previous quarter
The company's return on assets has shrunk by 82% YoY and by 17% QoQ
Orchestra BioMed Holdings's ROS has plunged by 61% YoY but it has increased by 18% from the previous quarter
Dividends
What is OBIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for OBIO.
Financial health
How did Orchestra BioMed Holdings financials performed over time
The company's total assets is 159% higher than its total liabilities
The company's total assets fell by 35% YoY but it rose by 4.1% QoQ
OBIO's total liabilities is down by 21% YoY but it is up by 3% QoQ
Orchestra BioMed Holdings's debt is 96% less than its equity
Orchestra BioMed Holdings's debt has plunged by 84% YoY but it has increased by 27% from the previous quarter
The debt to equity has shrunk by 71% YoY but it is up by 33% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.